Literature DB >> 11152837

Hemodynamic effects of inhaled nitric oxide in women with mitral stenosis and pulmonary hypertension.

P D Mahoney1, E Loh, L R Blitz, H C Herrmann.   

Abstract

Mitral stenosis (MS) is associated with elevated left atrial pressure, increased pulmonary vascular resistance (PVR), and pulmonary hypertension (PH). The hemodynamic effects of inhaled nitric oxide (NO) in adults with MS are unknown. We sought to determine the acute hemodynamic effects of inhaled NO in adults with MS and PH. Eighteen consecutive women (mean age 58 +/- 15 years) with MS and PH underwent heart catheterization. Hemodynamic measurements were recorded at baseline, after NO inhalation at 80 ppm, and after percutaneous balloon valvuloplasty (n = 10). NO reduced pulmonary artery systolic pressure (62 +/- 14 mm Hg [baseline] vs 54 +/- 15 mm Hg [NO]; p <0.001) and PVR (3.7 +/- 2.5 Wood U [baseline] vs 2.2 +/- 1.4 Wood U [NO]; p <0.001). NO had no effect on mean aortic pressure, left ventricular end-diastolic pressure, left atrial pressure, cardiac output, or systemic vascular resistance. Mitral valve area increased after valvuloplasty (0.9 +/- 0.2 cm2 [baseline] vs 1.6 +/- 0.3 cm2 [postvalvuloplasty]; p <0.001). A decrease in left atrial pressure (25 +/- 4 mm Hg [baseline] vs 17 +/- 4 mm Hg [after valvuloplasty]; p <0.001) and pulmonary artery systolic pressure (58 +/- 12 mm Hg [baseline] vs 45 +/- 8 mm Hg [after valvuloplasty]; p <0.001) was observed after valvuloplasty. No change in cardiac output or PVR was observed. Thus inhaled NO, but not balloon valvuloplasty, acutely reduced PVR in women with MS and PH. This suggests that a reversible, endothelium-dependent regulatory abnormality of vascular tone is an important mechanism of elevated PVR in MS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152837     DOI: 10.1016/s0002-9149(00)01314-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Pulmonary hypertension caused by pulmonary venous hypertension.

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

2.  Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement.

Authors:  Brian R Lindman; Alan Zajarias; Hersh S Maniar; D Craig Miller; Rakesh M Suri; Suzanne V Arnold; John Webb; Lars G Svensson; Susheel Kodali; Ke Xu; Girma M Ayele; Fay Lin; Shing-Chiu Wong; Vasilis Babaliaros; Vinod H Thourani; Pamela S Douglas; Scott Lim; Martin B Leon; Michael J Mack
Journal:  Heart       Date:  2015-08-11       Impact factor: 5.994

3.  Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic?

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

4.  Persistent pulmonary artery hypertension in patients undergoing balloon mitral valvotomy.

Authors:  Krishna Kumar Mohanan Nair; Harikrishnan Sivadasan Pillai; Thomas Titus; Ajitkumar Varaparambil; Sivasubramonian Sivasankaran; Kavassery Mahadevan Krishnamoorthy; Narayanan Namboodiri; Bijulal Sasidharan; Anees Thajudeen; Sanjay Ganapathy; Jaganmohan Tharakan
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

5.  Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature.

Authors:  Ilaria Botta; Jacques Devriendt; Jose Castro Rodriguez; Marielle Morissens; Andrew Carling; Leonel Barreto Gutierrez; Thierry Preseau; David De Bels; Patrick M Honore; Sebastien Redant
Journal:  J Transl Int Med       Date:  2018-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.